Analyst Scoreboard: 5 Ratings For Conmed

Ratings for Conmed (NYSE:CNMD) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $109.8, a high estimate of $129.00, and a low estimate of $98.00. A decline of 11.45% from the prior average price target is evident in the current average.

Exploring Analyst Ratings: An In-Depth Overview

A comprehensive examination of how financial experts perceive Conmed is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Conmed. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Conmed's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Conmed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Conmed analyst ratings.

Unveiling the Story Behind Conmed

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.

Unraveling the Financial Story of Conmed

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Revenue Growth: Over the 3 months period, Conmed showcased positive performance, achieving a revenue growth rate of 30.37% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Conmed's net margin excels beyond industry benchmarks, reaching 10.11%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Conmed's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.06% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Conmed's ROA stands out, surpassing industry averages. With an impressive ROA of 1.43%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Conmed's debt-to-equity ratio stands notably higher than the industry average, reaching 1.17. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.